Page 1 of 3
You will find here information about specific actions you can take—by phone, e-mail, fax—to help people with EDS and their families or information important to your health.
To find the addresses of national elected officials, you can use these links:
U.S. Senate: Senators Home
U.S. House of Representatives
For state, city and county information, try this directory:
State and Local Government on the Net
There are several upcoming changes that are going to be implemented as part of the Affordable Health Care Act beginning September 23, 2010. These include:
1Extending dependent coverage: Young adults who were usually removed from their parents’ insurance are now permitted to receive coverage under their parents’ insurance until the age of 26, even if the young adult no longer lives with his or her parents, is no longer a student, or is not a dependent on a parent’s tax return.
2Eliminating lifetime limits and restricting use of annual limits: All health insurance companies will be prohibited from imposing lifetime limits on essential benefits, such as hospital stays, and restricting annual limits.
3Eliminating pre-existing conditions exclusions for children: Job-based and new individual health insurance plans won’t be allowed to deny or exclude coverage to any child under age 19 based on a pre-existing condition, including a disability. Starting in 2014, these same plans won’t be able to exclude anyone (children and adults) from coverage or charge a higher premium for a pre-existing condition including a disability.
For more information about the implementation of the Affordable Health Care Act, please visit www.healthcare.gov.
Position Statement on Access to Pain Care
Release Date: August 26, 2010
is a serious and costly public health issue — together, acute and
chronic pain significantly and negatively affects the lives of an
estimated one out of every four Americans, costing more than $100
billion each year in medical claims, disability payments, lost wages and
lost productivity.i This figure does not begin to cover the physical,
emotional and economic strain of pain on the individual and his or her
family members and friends.
Unfortunately, many barriers exist in
our society and culture that place access to pain management out of
reach for many Americans. Barriers are multifaceted and entrenched,
ranging from a lack of pain providers who are knowledgeable and willing
to provide appropriate pain care, to financial affordability,
disparities and discrimination, and unnecessarily restrictive
regulation. Furthermore, unintended consequences exist in policy,
third-party payer rulings and professional conduct based on fear and
stigma that continue to erode access to effective pain management among
those who are suffering.
The effects of pain on the individual
and society can be alleviated or managed with proper medical attention.
Early intervention can reduce health care costs, limit disability and
dramatically improve the lives of people living with pain and their
The American Pain Foundation (APF)
advocates for improved access to effective pain care as a guiding
principle and integral part of its mission. People experiencing pain
have a basic human right to timely, appropriate and effective treatment
Access to care is a difficult and burdensome barrier for
people with pain in receiving appropriate pain care and for our society
at large, and requires an elevated collaborative effort to overcome.
APF views the goal of access to care as:
* Timely and appropriate pain care that includes access to the full
range of legal, safe and effective treatment options for all
individuals, regardless of race, ethnicity, gender, age, socioeconomic
or insurance status, to lessen pain, promote recovery, restore function
and improve quality of life.
* Individual comprehensive
multimodal pain management plans devised by the person with pain and
his/her health care team. Such plans will address complex factors, such
as the patient’s health status, clinical and social circumstances, pain
condition, severity and functional impact of pain, patient preference,
provider experience and availability.
* Use of multimodal
treatment approaches tailored to the individual living with pain,
including reasonable access to medically appropriate options such as
pharmacotherapy, psychosocial intervention, physical rehabilitation,
integration of complementary and alternative medicine (CAM), injection
and infusion therapies, implantable devices and surgical intervention.
Treatment options must include access to medications, including
controlled substances, as necessary for an individual’s pain treatment.
Such medications should be used according to FDA-approved indications or
other uses justified by research and clinical experience.
It is a
moral imperative to help people living with pain achieve a standard of
life deemed worthy of living — one that permits individuals to enjoy
their family members and friends, as well as contribute to our society
and economy. To this end, all people in pain have a right to timely,
appropriate and effective pain care.
APF believes access to care can be improved by:
* Educating the medical community and the public that chronic
persistent pain is a disease state that requires medical attention and
* Adapting disease management principles to guide primary care and appropriate specialty referral.
* Implementing standards and monitoring practices within all health
care systems and ensuring that transparency of pain care is an indicator
in satisfaction surveys and other institutional quality ratings (e.g.,
National Committee for Quality Assurance, Joint Commission on
Accreditation of Healthcare Organizations).
* Developing and implementing state specific report cards on practice and access using the Pain & Policy Studies Group (www.painpolicy.wisc.edu
) model for state policy report cards.
* Identifying and eliminating regulatory and third-party payer
policies and medical practices that usurp the “doctor-patient”
relationship or deny pain care access to vulnerable groups or those
policies that are primarily developed for cost savings that may
supersede the best interest of patient care and serve as an
inappropriate and unacceptable form of health care rationing.
Ensuring that reimbursement is compatible with the time required for
effective pain assessment and treatment and that it includes
multi-disciplinary/multimodal practice of care.
APF calls on the
professional medical community, regulators and all concerned
stakeholders to partner with people living with pain in taking action.
Organizational leaders and members alike must reaffirm the ethical
commitment to the care of people living with pain and re-energize
collaborative efforts to strategically address the problems related to
accessing pain care and the barriers preventing care. Medical,
governmental, non-profit and private sector parties must work together
to improve clinical and economic outcomes associated with acute and
chronic pain. The overwhelming evidence of harm resulting from inaction
serves as an irrefutable call to action.
i. National Centers for Health Statistics, Chartbook on Trends in the Health of Americans 2006, Special Feature: Pain. Page 70. www.cdc.gov/nchs/data/hus/hus06.pdf
Accessed August 24, 2010. National Institutes of Health. NIH Guide: New
Directions in Pain Research I. September 4, 1998. Available from http://grants.nih.gov/grants/guide/pa-files/PA-98-102.html
. Accessed August 24, 2010.
Reinforces Negative Pain Stigmas
Newsweek.com recently ran an article titled,
“Prescription Nation: Why we should worry about prescription drug
abuse,” that was not only one-sided and focused on deaths from pain
medication abuse and misuse, but ultimately reinforced the stigmas and
stereotypes associated with pain and pain management. With a readership of
more than four million, this alarmist article only contributes to barriers
for people in pain.
While abuse and misuse of prescription
medicines are a serious safety concern, with often devastating consequences,
writer Raina Kelley failed to explore and share personal accounts from some
people with pain whose needless suffering is ended and quality of life is
significantly improved by taking prescription pain medication as directed
and prescribed appropriately by knowledgeable health care providers.
APF was particularly concerned with
several biased and unfounded comments in the article, including a quote
from a doctor who works at an addiction treatment center who stated:
“Opioids are really dangerous…Boomers, of course are entering
their 60s, and with age comes all kinds of pain problems. If boomers
aren’t treated properly, they, too, go overboard.” This comment
is insulting and insinuates that this generation will become a group of
addicts if they are prescribed opioid medications. Unfortunately, the
article did not contain any quotes from an expert qualified to speak about
addiction and pain.
Lastly, Kelley focused on celebrity
deaths linked to prescription pain medication and questions how many more celebrity
deaths are “needed” before people pay attention. She failed to
mention how many people have died from untreated or undertreated pain and
the cost of pain to our society. Every sensationalized celebrity overdose
death only makes it more difficult for the more than 76.5 million Americans
who have or have had a problem with pain to be believed and treated in a
fair, unbiased way.
NEED YOUR HELP IN STOPPING THIS ONE-SIDED MEDIA COVERAGE
We encourage anyone affected by pain,
including people with pain, loved ones, caregivers, and health care
providers to join us by submitting a letter to the editor and posting an
online comment, insisting that Newsweek act responsibly
and demanding balanced reporting with accurate information about prescription
- Tell Newsweek that you are outraged by Kelley’s one-sided article.
- Include personal examples about how the stigmas associated
with pain have affected you, a family member or one of your patients.
- Give examples of how — when untreated — pain has
negatively impacted all aspects of life while living with pain (e.g.,
difficulties getting out of bed or performing self care, interfering
with your work, inability to hold or play with your children or
- State how, when properly treated, your life or a
patient’s life can return to some sense of normalcy.
- Encourage Newsweek to do a follow-up interview
with an expert who is qualified to speak about pain and addiction.
- Reiterate that the lives and livelihoods of people lost to pain
are worth no less than the celebrities and others who have died after
abusing or misusing prescription pain medication. Untreated pain
has been shown to shorten the lives of those who suffer — some
who no longer consider their lives worth living see suicide as their
- Reinforce that regardless of people who abuse or misuse pain
medication, people in pain have a right to timely and effective pain
- Read the full Newsweek article.
- Send your letters and comments directly to Newsweek at
Letters should be under 200 words. Include “Raina Kelley
article” in your subject line.
- Post a comment in the comment section immediately following
the online article. Follow posting directions on the web page.
- Share this article with your family members, friends,
colleagues, health care providers and encourage them to respond to Newsweek.
Don’t forget your Facebook and Twitter contacts.
- Please let us know when you have taken action by simply
cutting and pasting your message to Newsweek into an
email message and send to APF at
To assist you further in your letter, click
here to view our Reporter’s Guide that includes information
about pain, prescription pain medication and how untreated pain impacts
Thank you in advance for your response
to Newsweek. We
cannot do this alone — by combining our voices we can Conquer Pain
Opportunity to Assist FDA on Medical Device Issues
July 30, 2010
TO: NORD Member Organizations
FROM: Suki Bagal, MD
NORD has been invited to provide referrals of adult patients or patient
advocates who are interested in working with FDA’s Center for Devices and Radiologic
Health (CDRH) on issues related to medical devices. This could include
participation in CDRH work groups or listening sessions, or participation as a
Special Government Employee (SGE) at advisory panel meetings.
Names and contact information for anyone interested in working with FDA for
this purpose should be submitted by email or fax to:
Helene D. Clayton-Jeter, OD
Office of Special Health Issues
U.S. Food and Drug Administration
Phone: 301 796-8460
Fax: 301 847-8623
Please feel free to let her know you heard about this opportunity through
July 30, 2010
Register Online Now
for Rare Disease Investigator Training Course
registration was launched today for the three-day training course on conducting
research on rare diseases and orphan products to be offered Oct. 18-20 in Rockville, MD, by FDA and
NIH in collaboration with NORD and Duke
interested in participating in this course should register soon.
course will focus on FDA’s regulatory requirements
and clinical trial issues that are especially relevant to rare disease
research. It is designed for academic clinician-researchers, medical professionals participating in rare disease
clinical trials, and medical professionals
from small biotechnology and pharmaceutical companies conducting research on
June 3, 2010
New Educational Resources on Law
Against Genetic Discrimination Now Available
WASHINGTON, DC – June 3,
2010 – With
genetic testing becoming increasingly pervasive in medical care and our
lives, three of the most prominent organizations in genetics—the
Public Policy Center at Johns Hopkins University, the National Coalition
Health Professional Education in Genetics, and Genetic Alliance—have
teamed up to
produce educational materials about the Genetic Information
Act (GINA), a landmark federal law that protects individuals from the
genetic information in health insurance and employment.
2008 after 13 years of debate in Congress, GINA limits health insurers
using a person’s genetic information to set eligibility requirements, or
establish premium or contribution amounts. The law also prohibits
from using genetic information in decisions about hiring, firing, job
assignments or promotions.
“Almost every day, our center is asked for more detailed information
GINA means,” said Joan Scott, director of the Genetics and Public Policy
Center. “These targeted materials will go a long way towards answering
questions that still exist, paving the way for successful, long-term
implementation of this important law.”
materials will help health-care providers and members of the
public understand their rights and responsibilities under the law and
essential information about its details. The documents are also clear
what GINA doesn’t cover.
materials—including an interactive website, “GINA & You”
information sheet, and slide set for advocacy organizations—are
available, at http://www.GINAHelp.org,
Genetic Alliance Resource
Repository, and on Genetic Alliance’s website, http://www.geneticalliance.org
website also includes a history of GINA’s long struggle and passage.
has waited a long time for these protections, and by providing this
information as a resource we are helping individuals become informed
of genetic services,” said Sharon Terry, president and CEO of Genetic
for health-care providers include background documents, a discussion
guide suggesting how and when to talk about GINA with patients, a
slide set, and case studies that describe how the law works in a variety
real-world, clinical settings. These materials are available on the
the National Coalition for Health Professional Education in Genetics
“We’ve heard many questions already from health-care providers about the
specifics of GINA,” said Joseph McInerney, NCHPEG’s executive director.
“Especially as genetic testing becomes more common and the value of
history more apparent, there’s a real need for these materials to
providers and patients alike that GINA supports excellent clinical
and Public Policy Center (GPPC), part of the Johns Hopkins Berman
Institute of Bioethics, will have all of the materials on its website,
GPPC’s site also includes FAQs and other fact sheets about GINA aimed at
the materials was supported by a grant from The Pew Charitable Trusts.
Genetic Alliance is a national, nonprofit health advocacy organization
Washington, DC committed to transforming health through genetics and
an environment of openness centered on the health of individuals,
communities. When GINA was signed into law, the Alliance chaired the
for Genetic Fairness, a multi-stakeholder coalition of over 500
committed to passing federal genetic nondiscrimination legislation.
for Health Professional Education in Genetics: http://www.nchpeg.org
NCHPEG is a Maryland-based nonprofit organization whose mission is to
genetics education for all health professionals. NCHPEG’s membership
a broad range of professional societies, advocacy groups, corporate
and government agencies dedicated to the integration of genetically
health care into mainstream practice.
Public Policy Center: http://www.dnapolicy.org
The Genetics and Public Policy Center in the Berman Institute of
Johns Hopkins University was created to help policymakers, the press,
public understand and respond to the challenges and opportunities of
medicine and it potential to transform global public health.
About Genetic Alliance
Genetic Alliance transforms health
genetics, promoting an environment of openness centered on the health of
individuals, families, and communities. Genetic Alliance brings together
diverse stakeholders that create novel partnerships in advocacy;
individual, family, and community perspectives to improve health
revolutionizes access to information to enable translation of research
services and individualized decision making. For more information about
Alliance, visit http://www.geneticalliance.org
Hearing on Review and Regulation of Products for Rare Diseases
and Drug Administration (FDA) has announced that it will hold a public
on June 29 and 30 on the agency’s regulation of drugs, biologics and
for the diagnosis and treatment of rare diseases. The intent is to gain
input from patients, industry, healthcare providers, academic
others to help shape the future work of FDA’s committee for rare
representative will speak at the meeting. We encourage our Member
Organizations also to submit requests to speak or, if unable to attend
hearing, to submit written comments. Those wishing to speak must
of a patient organization who would like to connect with NORD
regarding speaking at the hearing or submitting comments afterward may
Diane Dorman at NORD’s Washington Office (
hearing will be held from 9 a.m. to 5 p.m. on June 29 and 30 at 10903
New Hampshire Avenue,
Building 31, Room 1503, Silver Spring,
committee for rare diseases was established in March 2010 to consider
agency reviews data from non-clinical studies and clinical trials, and
decisions about marketing authorization and postmarketing surveillance
products being developed for the rare disease patient population.
is intended to provide advocates for patients with rare diseases,
healthcare providers, the pharmaceutical industry and other interested
an opportunity to relate their experience with, concerns about, and
for the way FDA regulates the scientific evaluation of, marketing
for, and postmarketing surveillance of products for rare diseases.
to be considered include whether orphan drug marketing applications
should continue to be reviewed under the same process, and with the same
standards, as non-orphan products; whether the current processes
(Humanitarian Use Devices) adequately address the needs of rare disease
patients; whether current standards for approval of devices for rare
under the HDE (Humanitarian Device Exemption) mechanism remain
whether current processes for rare disease stakeholders to communicate
have been useful.
hearing is free and seating will be on a first-come, first-served
basis. Attendees who do not wish to make an oral presentation do not
to register. Anyone wishing to make an oral presentation during the
must register by submitting a written or electronic request to Paras M.
by May 31, 2010. For those unable to attend the hearing, written or
electronic comments will be accepted afterward until August 31.
about how to submit comments or requests for oral presentations,
and for additional information about the hearing, read the Federal Register
be directed to: Paras M. Patel, Food and Drug Administration, 10903 New
Hampshire Avenue, Building 32, Room 5271, Silver Spring, MD 20993-0002;
telephone: 301 796-8660; fax: 301 847 8621;
Life Caps Letter to Secretary
EDNF is proud of its advocacy actions and we want our members to know that we are signers of an important Life Caps Letter being sent to Secretary Sebelius. To read the letter, click here.
full-page ad by NORD in today’s edition of The
Politico, a newspaper distributed widely on Capitol Hill and
throughout Washington DC, urges the immediate end of annual and lifetime
insurance caps. As you know, private insurers may set lifetime and/or
annual caps on the amount of health care coverage an individual may have.
Americans with chronic diseases, rare disorders, or major medical crises
exhaust their insurance benefits under this system, forcing families into
financial crisis or even bankruptcy. NORD feels very strongly that annual
and lifetime caps on health insurance must be ended immediately.
reason for running the ad is as follows: The Senate health reform bill
currently under consideration is believed by many to include provisions for
ending lifetime and annual caps. However, certain provisions currently
within that bill would allow continuation of the caps for a period of years or
in many cases indefinitely. NORD is calling for changes in the language
of the bill to do away with these loopholes.
NORD’s ad, click
here. We will keep our members and friends informed of any new
developments on this important issue. In the meantime, if you have
stories to share with NORD about how annual or lifetime caps have affected you
or your members, please feel free to send them to
NORD Urges Senate to Pass Patient Protection and Affordable Health Care Act
On behalf of the nearly 30 million Americans with rare diseases, the National Organization for Rare Disorders (NORD) today delivered the following letter to U.S. Senate Majority Leader Harry Reid, and faxed copies to all members of the Senate:
November 19, 2009
The Honorable Harry Reid
United States Senate
Washington, DC 20510
Dear Majority Leader Reid:
On behalf of the 150 member organizations of the National Organization for Rare Disorders (NORD) representing nearly 30 million patients and families afflicted with one of the 7,000 known rare diseases, we are writing to convey our strong support for passage of the Patient Protection and Affordable Care Act. While this legislation has shortcomings and we will work to improve it before the President signs it into law, it is critically imperative the Senate votes to allow debate, to close debate, and to pass the Patient Protection and Affordable Care Act before the end of the year.
NORD members can no longer tolerate further delay in the passage and enactment of comprehensive health reform legislation. Our members are disproportionately burdened by the countless shortcomings of our health care system. They face untenable insurance access barriers through:
- Ongoing and unacceptable pre-existing condition exclusions and medical underwriting practices;
- Costly annual and lifetime caps;
- The absence of a federal guarantee issue requirement, and;
- Little to no direct financial assistance for those Americans who cannot afford insurance.
The Patient Protection and Affordable Care Act directly and helpfully addresses each one of these harmful shortcomings plaguing our nation’s health care system. With this in mind, we strongly believe that failure to act represents an explicit policy choice with severely negative consequences for our members and for all Americans. In short, health care reform delayed is health care access denied. As such, on behalf of all of our members, we urge you and all Members to promptly pass the Patient Protection and Affordable Care Act.
Thank you for the leadership that you, Chairmen Max Baucus, Christopher Dodd and Tom Harkin, as well as countless other Senators, have shown throughout this historical debate. We look forward to continuing our work with you and all Members on both sides of the aisle to finally achieve the long overdue business of ensuring affordable, quality coverage for all Americans.
Peter L. Saltonstall
President and CEO
Senator Max Baucus, Chairman, Senate Finance Committee
Senator Tom Harkin, Chairman, Senate Health, Educator, Labor and Pensions Committee
Senator Christopher Dodd, Chairman, Senate Banking, Housing and Urban Affairs
October 27, 2009
HOUSE OF REPRESENTATIVES
To date, 82 members of the House of Representatives have co-sponsored the bill, including eleven members of the Ways & Means Committee, which has jurisdiction over the legislation (see current list of co-sponsors below).
We have learned that House leadership plans to include I-ACT as part of
the health care reform bill now under debate.
However, as the fate of this legislation is uncertain, we continue to
gather additional co-sponsors in the House in order to also allow I-ACT to be
considered as a “suspension” bill, preserving another avenue for
its passage this year. In order to be considered for suspension, legislation
must be non-controversial, bi-partisan and, for bills referred to the Ways
& Means Committee as I-ACT is, it must have 100 co-sponsors.
The bill was introduced last month with seven co-sponsors. Senate rules do not require a threshold number for consideration as the House
does. This leaves two options for I-ACT in the Senate; it could either be
incorporated into the Senate’s version of health reform, or passed on its
own by “unanimous consent.”
I-ACT get 100 co-sponsors by writing or calling your U.S. Representative to ask
that he/she cosponsor this legislation that is so important to the rare disease
community. Offices may contact Amit Mistry or Binta Beard (202-225-2836) with
Representative Markey or Nicole Alexander (202-225-5744) with Representative
Stearns to co-sponsor.
Sen. Wyden for his support of I-ACT and urge him to pass it in 2009.
Read the final sign-on letter of endorsement for the “Improve Access to Clinical
NORD Advocacy Alert (October, 2009)
Help NORD Abolish Lifetime Insurance Caps!
As you read this, key Congressional leaders are behind closed doors determining what YOUR healthcare options will look like next year.
The time to act is now, by joining NORD and its Member Organizations in the following:
· Call the switchboard of the U.S. Congress at (202) 224-3121 and ask for your Representative’s office. Sen. Dorgan may also ask the Senate to abolish lifetime caps and will need these stories to explain the issue to his colleagues.
· Ask your Member of Congress to call Rep. Patrick Kennedy’s (D-RI) office to sign on to his letter to abolish lifetime caps.
· If you live in North Dakota and have been affected by lifetime insurance caps, please share your story with Senator Byron Dorgan (D-ND).
You can use the following phone script in your call to your legislator.
And…remember…the ultimate authority of the U.S. Congress to act resides in YOU! Together, we can make a difference!
Good morning/afternoon. My name is _____________________ and I am a constituent living in (city, state). I have a rare disease.
I am calling to bring to your attention a letter that Rep. Patrick Kennedy is circulating in Congress. This letter calls for the immediate abolition of lifetime insurance caps in the House health care reform bill, HR 3200.
As this bill is currently written, patients may have to wait up to nine years after reform is enacted to see those lifetime caps eliminated. People like me who have rare diseases face possible financial ruin if lifetime insurance caps are not immediately abolished. This issue is very important to me.
Will Representative (insert name of your Representative) sign on to Patrick Kennedy’s letter?
Please Help Us Educate Members of Congress About Lifetime Insurance Caps!
October 12, 2009
NORD has been excited to see the elimination of lifetime
caps included in each health reform proposal currently being considered by
Congress, the old adage "the devil is in the details" still rings
true. Although all of the bills eliminate lifetime
caps, in some proposals the
provision will be delayed and in others there is no requirement for existing plans. We need you to write
your members of Congress to ask for
lifetime caps to be prohibited immediately.
way the bills are currently drafted would result in many people potentially
facing lifetime caps, even after
health reform is enacted. Individuals with employer-sponsored insurance
could face caps until 2018 or possibly indefinitely if their insurance coverage
does not change. This is unacceptable. NORD has been advocating for the
immediate elimination of lifetime caps in both new and existing plans in all
leaders are currently working to combine the various health reform bills into
House and Senate versions before they can be voted on by each chamber.
Now is the time for everyone who
wants lifetime caps to be eliminated
to contact Congress.
e-mail your members of Congress
TODAY to ask that lifetime caps be
eliminated immediately. Sample
letters have been provided (see below) that you can personalize with
information about how your family or your members
are affected by insurance problems, the annual cost of care and, especially,
lifetime caps. If you have hit
a lifetime cap, please be sure to
include that as well.
find the e-mail addresses of your Senators and Representative go to:
you for your continued support. In this climate of change, it's VERY
important for all of us in the rare disease community to make our voices heard
on issues related to health reform.
copy Diane Dorman, Vice President for Public Policy, on your e-mails —
Safety Alert: Voluntary Recall of Children's Tylenol®
September 28, 2009
McNeil Consumer Healthcare, the Maker of Children's Tylenol®,
Announces a Voluntary Recall
discovering the possible contamination with Gram-negative bacteria,
Burkholderia cepacia, McNeil Consumer Healthcare, a division of Johnson
& Johnson, informed physicians and other providers of the recall in
a September 18, 2009 letter. The company reported that no bacteria had
been found in finished products, but bacteria were detected in an
examination of the bulk materials used to make the medicine.
cautioned that infection with the bacteria can be serious in high-risk
persons, including those with pulmonary disease, cystic fibrosis, or
immune systems that are otherwise compromised. Young children and
elders using these preparations for pain control should be warned.
recall covers 21 flavors of its pediatric acetaminophen product, and
several cold and cough medications that include acetaminophen,
manufactured from April 2008 through June 2008, which includes:
• Children's Tylenol® Suspension 4 oz. strawberry,
• Children's Tylenol® Pediatric Suspension 1 oz. cherry
• Infants' Tylenol® Suspension Drops 1/2 oz. grape
• For the complete list and associated lot numbers, see: http://www.tylenol.com/generic.jhtml?id=tylenol/news/subpchildinfantnews.inc.
Individuals who may have these medicines in their possession should:
• Stop taking this preparation if listed above.
• Contact your health care professional (HCP) if you or your child taking this medication has become suddenly ill
of exposure can range from no symptoms to severe breathing difficulties
especially in those with chronic lung disorders. For more information,
visit the CDC website: http://www.cdc.gov/ncidod/dhqp/id_BcepaciaFS.html
• Share this information with your HCP, pharmacist and insurance provider should there be additional questions.
The recall does NOT apply to children’s Tylenol® Meltaways or Junior Strength Tylenol® Meltaways.
McNeil has established a consumer call center at 800-962-5357 for parents or caregivers with questions.